AstraZeneca (LON: AZN) has agreed to sell the global commercial rights, excluding China, Japan, the US and Mexico, for Losec (omeprazole) and associated brands to Cheplapharm Arzneimittel GmbH (Cheplapharm). The..

AstraZeneca (LON: AZN) has today announced that Qtrilmet (metformin hydrochloride, saxagliptin and dapagliflozin) modified-release tablets have been recommended for marketing authorisation in the European Union for the treatment of adults..

AstraZeneca plc (LON:AZN) has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong and China Macau for Linzess* (linaclotide), a first-in-class new treatment for..

AstraZeneca plc (LON:AZN) today announced that it has received marketing authorisation from China’s National Medical Products Administration for Tagrisso as a 1st-line treatment for adults with locally-advanced or metastatic non-small..

Brilinta reduced the risk of cardiovascular events in patients with coronary artery disease and type-2 diabetes in Phase III THEMIS trial. Additionally, Brilinta showed a more favourable clinical benefit in..

AstraZeneca plc (LON:AZN) today announced detailed results from the landmark Phase III DAPA-HF trial that showed Farxiga on top of standard of care reduced both the incidence of cardiovascular death..

AstraZeneca plc (LON: AZN) today announced that the Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary..

AstraZeneca plc (LON:AZN) today announced positive results from the Phase III ETHOS trial for triple-combination therapy Breztri Aerosphere, formerly PT010, in patients with moderate to very severe chronic obstructive pulmonary..

AstraZeneca plc (LON:AZN) today announced that the US Food and Drug Administration has granted Orphan Drug Designation to Fasenra (benralizumab) for the treatment of eosinophilic oesophagitis (EoE). EoE is a..

AstraZeneca plc (LON:AZN) today announced that it has agreed to buy a US Food and Drug Administration Priority Review Voucher for a total cash consideration of $95m from a subsidiary..

AstraZeneca (LON: AZN) today announced that its partner FibroGen (China) Medical Technology Development Co., Ltd. (FibroGen China) has received marketing authorisation for roxadustat in China for the treatment of anaemia..

AstraZeneca plc (LON: AZN) today announced final overall survival results from the Phase III NEPTUNE trial, a randomised, open-label, multi-centre, global trial of Imfinzi (durvalumab) in combination with tremelimumab, an..

Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor..

AstraZeneca plc (LON:AZN) today announced that, with effect from 1 September 2019, Michel Demaré is appointed as a Non-Executive Director and a member of the Audit Committee. Leif Johansson, Chairman..

AstraZeneca plc (LON:AZN) today announced that the US Food and Drug Administration has granted Breakthrough Therapy Designation for Calquence as a monotherapy treatment for adult patients with chronic lymphocytic leukaemia,..

AstraZeneca plc (LON:AZN) and MSD Inc., known as Merck & Co., Inc. inside the US and Canada, today announced positive results from the Phase III PAOLA-1 trial in women with..

AstraZeneca plc (LON: AZN) today announced positive overall survival results from the Phase III FLAURA trial, a randomised, double-blinded, multi-centre trial of Tagrisso (osimertinib) in previously-untreated patients with locally-advanced or..

AstraZeneca plc (LON: AZN) and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced positive results from the Phase III..